Understanding how alpha-synuclein affects cell membranes in Parkinson's disease

PROVIDE NEW INSIGHTS IN ALPHA-SYNUCLEIN INDUCED CELL MEMBRANE DISRUPTION USING SCANNING ION CONDUCTANCE MICROSCOPY AND SURFACE PLASMON RESONANCE MICROSCOPY

NIH-funded research California State University Los Angeles · NIH-10974782

This study is looking at how a protein called alpha-synuclein, which is connected to Parkinson's disease, affects brain cells and how things like tiny plastic particles in the environment might make it worse, all to find new ways to help people with Parkinson's.

Quick facts

Grant typeR15 grant
Study typeNIH-funded research
Funding institutionCalifornia State University Los Angeles NIH-funded
Lab location1 site (Los Angeles, United States)
Project IDNIH-10974782 on NIH RePORTER

What this research studies

This research investigates the role of alpha-synuclein, a protein linked to Parkinson's disease, in disrupting neuronal cell membranes. Using advanced imaging techniques like scanning ion conductance microscopy and surface plasmon resonance microscopy, the study aims to explore how different forms of alpha-synuclein, particularly its phosphorylated variant, impact neuronal health. The research will also examine the effects of environmental toxins, such as nanoplastics, on alpha-synuclein aggregation and its interactions with cell membranes. By deepening our understanding of these mechanisms, the research seeks to identify potential therapeutic targets for Parkinson's disease.

Who could benefit from this research

Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease or those at risk due to genetic or environmental factors.

Not a fit: Patients with other neurodegenerative disorders unrelated to alpha-synuclein may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new therapeutic strategies for treating Parkinson's disease.

How similar studies have performed: Previous research has shown promising results in understanding alpha-synuclein's role in neurodegeneration, indicating that this approach has potential for success.

Where this research is happening

Los Angeles, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.